Abstract

Lung cancer is a major cause of mortality worldwide and non-small cell lung cancer (NSCLC) accounts for over 80% of all cases of lung cancer. Despite efforts to develop and improve early screening methods, the majority of tumors are detected at advanced stages. For over 30 years, cisplatin (CDDP), or any of its analogues, has been used in the treatment of many types of tumors, including lung cancer. The use of platinum-based chemotherapeutics is limited by their toxicity and later on by the development of chemoresistance by tumor cells. The molecular mechanisms of CDDP resistance are not fully resolved. Genetic variants of DNA repair proteins, as well as proteins involved in drug accumulation or detoxification, play a crucial role in determining the cell’s response to platinum-based chemotherapy. The identification of selected gene polymorphisms could improve the prognosis of a patient’s response to therapy and overall survival. In this review we will focus on the gene polymorphisms involved in CDDP resistance, in particular in lung tumors, and discuss their potential as prognosis and survival markers.

References

• 1. Austin G.E., Lam L., Zaki S.R., Chan W.C., Hodge T., Hou J., SwanD., Zhang W., Racine M., Whitsett C. i wsp.: Sequence comparison ofputative regulatory DNA of the 5’ flanking region of the myeloperoxidasegene in normal and leukemic bone marrow cells. Leukemia,1993; 7: 1445-1450
  Google Scholar
• 2. Basu A., Krishnamurthy S.: Cellular responses to Cisplatin-inducedDNA damage. J. Nucleic Acids, 2010; 2010: 201367
  Google Scholar
• 3. Bernal S.D., Speak J.A., Boeheim K., Dreyfuss A.I., Wright J.E., TeicherB.A., Rosowsky A., Tsao S.W., Wong Y.C.: Reduced membraneprotein associated with resistance of human squamous carcinomacells to methotrexate and cis-platinum. Mol. Cell. Biochem., 1990;95: 61-70
  Google Scholar
• 4. Binks S.P., Dobrota M.: Kinetics and mechanism of uptake of platinum-basedpharmaceuticals by the rat small intestine. Biochem.Pharmacol., 1990; 40: 1329-1336
  Google Scholar
• 5. Booton R., Ward T., Heighway J., Ashcroft L., Morris J., ThatcherN.: Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-basedchemotherapy, and non-small cell lung cancer. J. Thorac.Oncol., 2006; 1: 679-683
  Google Scholar
• 6. Booton R., Ward T., Heighway J., Taylor P., Power F., Ashcroft L.,Morris J., Thatcher N.: Xeroderma pigmentosum group D haplotypepredicts for response, survival, and toxicity after platinum-basedchemotherapy in advanced nonsmall cell lung cancer. Cancer,2006; 106: 2421-2427
  Google Scholar
• 7. Borst P., Jonkers J., Rottenberg S.: What makes tumors multidrugresistant? Cell Cycle, 2007; 6: 2782-2787
  Google Scholar
• 8. Borst P., Rottenberg S., Jonkers J.: How do real tumors becomeresistant to cisplatin? Cell Cycle, 2008; 7: 1353-1359
  Google Scholar
• 9. Brozovic A., Ambriović-Ristov A., Osmak M.: The relationship betweencisplatin-induced reactive oxygen species, glutathione, andBCL-2 and resistance to cisplatin. Crit. Rev. Toxicol., 2010; 40: 347-359
  Google Scholar
• 10. Butkiewicz D., Drosik A., Suwiński R., Krześniak M., Rusin M.,Kosarewicz A., Rachtan J., Matuszczyk I., Gawkowska-Suwińska M.:Influence of DNA repair gene polymorphisms on prognosis in inoperablenon-small cell lung cancer patients treated with radiotherapyand platinum-based chemotherapy. Int. J. Cancer, 2012; 131:E1100-E1108
  Google Scholar
• 11. Butkiewicz D., Rusin M., Sikora B., Lach A., Chorąży M.: An associationbetween DNA repair gene polymorphisms and survival inpatients with resected non-small cell lung cancer. Mol. Biol. Rep.,2011; 38: 5231-5241
  Google Scholar
• 12. Camps C., Sarries C., Roig B., Sanchez J.J., Queralt C., Sancho E.,Martinez N., Tarón M., Rosell R.: Assessment of nucleotide excisionrepair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin-treated advanced non-small-cell lung cancer patients. Clin.Lung Cancer, 2003; 4: 237-241
  Google Scholar
• 13. Chen H.Y., Yu S.L., Chen C.H., Chang G.C., Chen C.Y., Yuan A.,Cheng C.L., Wang C.H., Terng H.J., Kao S.F., Chan W.K., Li H.N., Liu C.C., Singh S., Chen W.J., Chen J.J., Yang P.C.: A five-gene signatureand clinical outcome in non-small-cell lung cancer. N. Engl. J. Med.,2007; 356: 11-20
  Google Scholar
• 14. Chen H.Y., Yu S.L., Li K.C., Yang P.C.: Biomarkers and transcriptomeprofiling of lung cancer. Respirology, 2012; 17: 620-626
  Google Scholar
• 15. Chen S., Huo X., Lin Y., Ban H., Lin Y., Li W., Zhang B., Au W.W.,Xu X.: Association of MDR1 and ERCC1 polymorphisms with responseand toxicity to cisplatin-based chemotherapy in non-small-celllung cancer patients. Int. J. Hyg. Environ. Health, 2010; 213: 140-145
  Google Scholar
• 16. Chen S., Tang D., Xue K., Xu L., Ma G., Hsu Y., Cho S.S.: DNA repairgene XRCC1 and XPD polymorphisms and risk of lung cancer ina Chinese population. Carcinogenesis, 2002; 23: 1321-1325
  Google Scholar
• 17. Cobo M., Isla D., Massuti B., Montes A., Sanchez J.M., ProvencioM., Viñolas N., Paz-Ares L., Lopez-Vivanco G., Muñoz M.A., Felip E.,Alberola V., Camps C., Domine M., Sanchez J.J., Sanchez-Ronco M.,Danenberg K., Taron M., Gandara D., Rosell R.: Customizing cisplatinbased on quantitative excision repair cross-complementing 1mRNA expression: a phase III trial in non-small-cell lung cancer. J.Clin. Oncol., 2007; 25: 2747-2754
  Google Scholar
• 18. Cote M.L., Kardia S.L., Wenzlaff A.S., Land S.J., Schwartz A.G.:Combinations of glutathione S-transferase genotypes and risk ofearly-onset lung cancer in Caucasians and African Americans: a population-basedstudy. Carcinogenesis, 2005; 26: 811-819
  Google Scholar
• 19. Cote M.L., Wenzlaff A.S., Bock C.H., Land S.J., Santer S.K., SchwartzD.R., Schwartz A.G.: Combinations of cytochrome P-450 genotypes andrisk of early-onset lung cancer in Caucasians and African Americans:a population-based study. Lung Cancer, 2007; 55: 255-262
  Google Scholar
• 20. Cummings M., Higginbottom K., McGurk C.J., Wong O.G., KöberleB., Oliver R.T., Masters J.R.: XPA versus ERCC1 as chemosensitisingagents to cisplatin and mitomycin C in prostate cancer cells: roleof ERCC1 in homologous recombination repair. Biochem. Pharmacol.,2006; 72: 166-175
  Google Scholar
• 21. Danesi R., Pasqualetti G., Giovannetti E., Crea F., Altavilla G., DelTacca M., Rosell R.: Pharmacogenomics in non-small-cell lung cancerchemotherapy. Adv. Drug Deliv. Rev., 2009; 61: 408-417
  Google Scholar
• 22. Eastman A.: Cross-linking of glutathione to DNA by cancer chemotherapeuticplatinum coordination complexes. Chem. Biol. Interact.,1987; 61: 241-248
  Google Scholar
• 23. Gately D.P., Howell S.B.: Cellular accumulation of the anticanceragent cisplatin: a review. Br. J. Cancer, 1993; 67: 1171-1176
  Google Scholar
• 24. Giachino D.F., Ghio P., Regazzoni S., Mandrile G., Novello S.,Selvaggi G., Gregori D., DeMarchi M., Scagliotti G.V.: Prospective assessmentof XPD Lys751Gln and XRCC1 Arg399Gln single nucleotidepolymorphisms in lung cancer. Clin. Cancer Res., 2007; 13: 2876-2881
  Google Scholar
• 25. Gurubhagavatula S., Liu G., Park S., Zhou W., Su L., Wain J.C.,Lynch T.J., Neuberg D.S., Christiani D.C.: XPD and XRCC1 geneticpolymorphisms are prognostic factors in advanced non-small-celllung cancer patients treated with platinum chemotherapy. J. Clin.Oncol., 2004; 22: 2594-2601
  Google Scholar
• 26. Han J.Y., Lim H.S., Yoo Y.K., Shin E.S., Park Y.H., Lee S.Y., LeeJ.E., Lee D.H., Kim H.T., Lee J.S.: Associations of ABCB1, ABCC2, andABCG2 polymorphisms with irinotecan-pharmacokinetics and clinicaloutcome in patients with advanced non-small cell lung cancer.Cancer, 2007; 110: 138-147
  Google Scholar
• 27. Hildebrandt M.A., Gu J., Wu X.: Pharmacogenomics of platinum–based chemotherapy in NSCLC. Expert Opin. Drug. Metab. Toxicol.,2009; 5: 745-755
  Google Scholar
• 28. Ho R.H., Kim R.B.: Transporters and drug therapy: implications fordrug disposition and disease. Clin. Pharmacol. Ther., 2005; 78: 260-277
  Google Scholar
• 29. Holzer A.K., Manorek G.H., Howell S.B.: Contribution of themajor copper influx transporter CTR1 to the cellular accumulationof cisplatin, carboplatin, and oxaliplatin. Mol. Pharmacol., 2006;70: 1390-1394
  Google Scholar
• 30. Hsu Y.C., Yuan S., Chen H.Y., Yu S.L., Liu C.H., Hsu P.Y., Wu G.,Lin C.H., Chang G.C., Li K.C., Yang P.C.: A four-gene signature fromNCI-60 cell line for survival prediction in non-small cell lung cancer.Clin. Cancer Res., 2009; 15: 7309-7315
  Google Scholar
• 31. Huang Y.T., Heist R.S., Chirieac L.R., Lin X., Skaug V., ZienolddinyS., Haugen A., Wu M.C., Wang Z., Su L., Asomaning K., ChristianiD.C.: Genome-wide analysis of survival in early-stage non-small-celllung cancer. J. Clin. Oncol., 2009; 27: 2660-2667
  Google Scholar
• 32. Huang Y., Liu X., Kuang X., Liao D.: CYP2D6 T188C variant is associatedwith lung cancer risk in the Chinese population. TumourBiol., 2013; 34: 2189-2193
  Google Scholar
• 33. Huang Y., Sadée W.: Membrane transporters and channels inchemoresistance and -sensitivity of tumor cells. Cancer Lett., 2006;239: 168-182
  Google Scholar
• 34. Hung R.J., Boffetta P., Brockmöller J., Butkiewicz D., Cascorbi I.,Clapper M.L., Garte S., Haugen A., Hirvonen A., Anttila S., Kalina I., LeMarchand L., London S.J., Rannug A., Romkes M., Salagovic J., SchoketB., Gaspari L., Taioli E.: CYP1A1 and GSTM1 genetic polymorphismsand lung cancer risk in Caucasian non-smokers: a pooled analysis.Carcinogenesis, 2003; 24: 875-882
  Google Scholar
• 35. Hung R.J., Brennan P., Canzian F., Szeszenia-Dabrowska N., ZaridzeD., Lissowska J., Rudnai P., Fabianova E., Mates D., Foretova L.,Janout V., Bencko V., Chabrier A., Borel S., Hall J., Boffetta P.: Large–scale investigation of base excision repair genetic polymorphismsand lung cancer risk in a multicenter study. J. Natl. Cancer Inst.,2005; 97: 567-576
  Google Scholar
• 36. Isla D., Sarries C., Rosell R., Alonso G., Domine M., Taron M.,Lopez-Vivanco G., Camps C., Botia M., Nunez L., Sanchez-Ronco M.,Sanchez J.J., Lopez-Brea M., Barneto I., Paredes A., Medina B., ArtalA., Lianes P.: Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treatedadvanced non-small-cell lung cancer. Ann.Oncol., 2004; 15: 1194-1203
  Google Scholar
• 37. Jassem J., Biernat W., Drosik K., Dziadziuszko R., Kordek R., KozielskiJ., Kowalski D.M., Krzakowski M., Nikliński J., Olszewski W.,Orłowski T., Ramlau R., Roszkowski-Śliż K., Rzyman W.: Uaktualnionezalecenia dotyczące systemowego leczenia niedrobnokomórkowegoraka płuca i złośliwego międzybłoniaka opłucnej. Pneumonol. Alergol.Pol., 2010; 78: 418-431
  Google Scholar
• 38. Jaworowska E., Trubicka J., Lener M.R., Masojć B., Złowocka–Perłowska E., McKay J.D., Renard H., Oszutowska D., WokołorczykD., Lubiński J., Grodzki T., Serwatowski P., Nej-Wołosiak K., Tołoczko-GrabarekA., Sikorski A., Słojewski M., Jakubowska A., CybulskiC., Lubiński J., Scott R.J.: Smoking related cancers and loci at chromosomes15q25, 5p15, 6p22.1 and 6p21.33 in the Polish population.PLoS One, 2011; 6: e25057
  Google Scholar
• 39. Kartalou M., Essigmann J.M.: Mechanisms of resistance to cisplatin.Mutat. Res., 2001; 478: 23-43
  Google Scholar
• 40. Kartalou M., Essigmann J.M.: Recognition of cisplatin adductsby cellular proteins. Mutat. Res., 2001; 478: 1-21
  Google Scholar
• 41. Kelley S.L., Basu A., Teicher B.A., Hacker M.P., Hamer D.H., LazoJ.S.: Overexpression of metallothionein confers resistance to anticancerdrugs. Science, 1988; 241: 1813-1815
  Google Scholar
• 42. Larsen J.E., Colosimo M.L., Yang I.A., Bowman R., ZimmermanP.V., Fong K.M.: CYP1A1 Ile462Val and MPO G-463A interact to increaserisk of adenocarcinoma but not squamous cell carcinoma ofthe lung. Carcinogenesis, 2006; 27: 525-532
  Google Scholar
• 43. Lee K.M., Kang D., Clapper M.L., Ingelman-Sundberg M., Ono-KiharaM., Kiyohara C., Min S., Lan Q., Le Marchand L., Lin P., Lung M.L.,Pinarbasi H., Pisani P., Srivatanakul P., Seow A., Sugimura H., TokudomeS., Yokota J., Taioli E.: CYP1A1, GSTM1, and GSTT1 polymorphisms,smoking, and lung cancer risk in a pooled analysis among Asianpopulations. Cancer Epidemiol. Biomarkers Prev., 2008; 17: 1120-1126
  Google Scholar
• 44. Li W., Yue W., Zhang L., Zhao X., Ma L., Yang X., Zhang C., WangY., Gu M.: Polymorphisms in GSTM1, CYP1A1, CYP2E1, and CYP2D6 are associated with susceptibility and chemotherapy response innon-small-cell lung cancer patients. Lung, 2012; 190: 91-98
  Google Scholar
• 45. Liedert B., Materna V., Schadendorf D., Thomale J., Lage H.:Overexpression of cMOAT (MRP2/ABCC2) is associated with decreasedformation of platinum-DNA adducts and decreased G2-arrestin melanoma cells resistant to cisplatin. J. Invest. Dermatol., 2003;121: 172-176
  Google Scholar
• 46. Lin J., Swan G.E., Shields P.G., Benowitz N.L., Gu J., Amos C.I.,de Andrade M., Spitz M.R., Wu X.: Mutagen sensitivity and geneticvariants in nucleotide excision repair pathway: genotype-phenotypecorrelation. Cancer Epidemiol. Biomarkers Prev., 2007; 16:2065-2071
  Google Scholar
• 47. Lord R.V., Brabender J., Gandara D., Alberola V., Camps C., DomineM., Cardenal F., Sánchez J.M., Gumerlock P.H., Tarón M., SánchezJ.J., Danenberg K.D., Danenberg P.V., Rosell R.: Low ERCC1 expressioncorrelates with prolonged survival after cisplatin plus gemcitabinechemotherapy in non-small cell lung cancer. Clin. Cancer Res.,2002; 8: 2286-2291
  Google Scholar
• 48. Lu C., Spitz M.R., Zhao H., Dong Q., Truong M., Chang J.Y., BlumenscheinG.R. Jr., Hong W.K., Wu X.: Association between glutathioneS-transferase π polymorphisms and survival in patients withadvanced nonsmall cell lung carcinoma. Cancer, 2006; 106: 441-447
  Google Scholar
• 49. Maliepaard M., van Gastelen M.A., Tohgo A., Hausheer F.H., vanWaardenburg R.C., de Jong L.A., Pluim D., Beijnen J.H., Schellens J.H.:Circumvention of breast cancer resistance protein (BCRP)-mediatedresistance to camptothecins in vitro using non-substrate drugsor the BCRP inhibitor GF120918. Clin. Cancer Res., 2001; 7: 935-941
  Google Scholar
• 50. Matakidou A., el Galta R., Webb E.L., Rudd M.F., Bridle H., GELCAPSConsortium, Eisen T., Houlston R.S.: Genetic variation in theDNA repair genes is predictive of outcome in lung cancer. Hum. Mol.Genet., 2007; 16: 2333-2340
  Google Scholar
• 51. McWhinney S.R., Goldberg R.M., McLeod H.L.: Platinum neurotoxicitypharmacogenetics. Mol. Cancer Ther., 2009; 8: 10-16
  Google Scholar
• 52. Moyer A.M., Salavaggione O.E., Wu T.Y., Moon I., Eckloff B.W.,Hildebrandt M.A., Schaid D.J., Wieben E.D., Weinshilboum R.M.: Glutathiones-transferase p1: gene sequence variation and functionalgenomic studies. Cancer Res., 2008; 68: 4791-4801
  Google Scholar
• 53. Müller P.J., Dally H., Klappenecker C.N., Edler L., Jäger B., GerstM., Spiegelhalder B., Tuengerthal S., Fischer J.R., Drings P., BartschH., Risch A.: Polymorphisms in ABCG2, ABCC3 and CNT1 genes andtheir possible impact on chemotherapy outcome of lung cancer patients.Int. J. Cancer, 2009; 124: 1669-1674
  Google Scholar
• 54. Nakayama K., Kanzaki A., Terada K., Mutoh M., Ogawa K., SugiyamaT., Takenoshita S., Itoh K., Yaegashi N., Miyazaki K., Neamati N.,Takebayashi Y.: Prognostic value of the Cu-transporting ATPase inovarian carcinoma patients receiving cisplatin-based chemotherapy.Clin. Cancer Res., 2004; 10: 2804-2811
  Google Scholar
• 55. Olaussen K.A., Dunant A., Fouret P., Brambilla E., André F., HaddadV., Taranchon E., Filipits M., Pirker R., Popper H.H., Stahel R., SabatierL., Pignon J.P., Tursz T., Le Chevalier T., Soria J.C., IALT Bio Investigators:DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-basedadjuvant chemotherapy. N. Engl. J. Med., 2006; 355: 983-991
  Google Scholar
• 56. Olaussen K.A., Mountzios G., Soria J.C.: ERCC1 as a risk stratifierin platinum-based chemotherapy for nonsmall-cell lung cancer.Curr. Opin. Pulm. Med., 2007; 13: 284-289
  Google Scholar
• 57. Onkonet. Rak płuca. http://www.onkonet.pl/dp_rakpluca.html(15.11.2013)
  Google Scholar
• 58. Pan J.H., Han J.X., Wu J.M., Huang H.N., Yu Q.Z., Sheng L.J.: MDR1single nucleotide polymorphism G2677T/A and haplotype are correlatedwith response to docetaxel-cisplatin chemotherapy in patientswith non-small-cell lung cancer. Respiration, 2009; 78: 49-55
  Google Scholar
• 59. Pan J.H., Han J.X., Wu J.M., Sheng L.J., Huang H.N., Yu Q.Z.: MDR1single nucleotide polymorphisms predict response to vinorelbine–based chemotherapy in patients with non-small cell lung cancer.Respiration, 2008; 75: 380-385
  Google Scholar
• 60. Peklak-Scott C., Smitherman P.K., Townsend A.J., Morrow C.S.:Role of glutathione S-transferase P1-1 in the cellular detoxificationof cisplatin. Mol. Cancer Ther., 2008; 7: 3247-3255
  Google Scholar
• 61. Rabik C.A., Dolan M.E.: Molecular mechanisms of resistanceand toxicity associated with platinating agents. Cancer Treat. Rev.,2007; 33: 9-23
  Google Scholar
• 62. Rabik C.A., Maryon E.B., Kasza K., Shafer J.T., Bartnik C.M., DolanM.E.: Role of copper transporters in resistance to platinating agents.Cancer Chemother. Pharmacol., 2009; 64: 133-142
  Google Scholar
• 63. Rabindran S.K., Ross D.D., Doyle L.A., Yang W., Greenberger L.M.:Fumitremorgin C reverses multidrug resistance in cells transfectedwith the breast cancer resistance protein. Cancer Res., 2000; 60: 47-50
  Google Scholar
• 64. Roos W.P., Kaina B.: DNA damage-induced cell death: from specificDNA lesions to the DNA damage response and apoptosis. CancerLett., 2013; 332: 237-248
  Google Scholar
• 65. Rosell R., Lord R.V., Taron M., Reguart N.: DNA repair and cisplatinresistance in non-small-cell lung cancer. Lung Cancer, 2002; 38: 217-227
  Google Scholar
• 66. Rosell R., Taron M., Camps C., López-Vivanco G.: Influence ofgenetic markers on survival in non-small cell lung cancer. DrugsToday, 2003; 39: 775-786
  Google Scholar
• 67. Ryu J.S., Hong Y.C., Han H.S., Lee J.E., Kim S., Park Y.M., Kim Y.C.,Hwang T.S.: Association between polymorphisms of ERCC1 and XPDand survival in non-small-cell lung cancer patients treated with cisplatincombination chemotherapy. Lung Cancer, 2004; 44: 311-316
  Google Scholar
• 68. Samimi G., Varki N.M., Wilczynski S., Safaei R., Alberts D.S., HowellS.B.: Increase in expression of the copper transporter ATP7Aduring platinum drug-based treatment is associated with poor survivalin ovarian cancer patients. Clin. Cancer Res., 2003; 9: 5853-5859
  Google Scholar
• 69. Shah P.P., Singh A.P., Singh M., Mathur N., Mishra B.N., Pant M.C.,Parmar D.: Association of functionally important polymorphisms incytochrome P4501B1 with lung cancer. Mutat. Res., 2008; 643: 4-10
  Google Scholar
• 70. Shen L., Kondo Y., Ahmed S., Boumber Y., Konishi K., Guo Y.,Chen X., Vilaythong J.N., Issa J.P.: Drug sensitivity prediction by CpGisland methylation profile in the NCI-60 cancer cell line panel. CancerRes., 2007; 67: 11335-11343
  Google Scholar
• 71. Siddik Z.H.: Cisplatin: mode of cytotoxic action and molecularbasis of resistance. Oncogene, 2003; 22: 7265-7279
  Google Scholar
• 72. Simon G.R., Sharma S., Cantor A., Smith P., Bepler G.: ERCC1expression is a predictor of survival in resected patients with non–small cell lung cancer. Chest, 2005; 127: 978-983
  Google Scholar
• 73. Sohn J.W., Lee S.Y., Lee S.J., Kim E.J., Cha S.I., Kim C.H., Lee J.T.,Jung T.H., Park J.Y.: MDR1 polymorphisms predict the response toetoposide-cisplatin combination chemotherapy in small cell lungcancer. Jpn. J. Clin. Oncol., 2006; 36: 137-141
  Google Scholar
• 74. Song I.S., Savaraj N., Siddik Z.H., Liu P., Wei Y., Wu C.J., Kuo M.T.:Role of human copper transporter Ctr1 in the transport of platinum–based antitumor agents in cisplatin-sensitive and cisplatin-resistantcells. Mol. Cancer Ther., 2004; 3: 1543-1549
  Google Scholar
• 75. Sørensen M., Autrup H., Tjønneland A., Overvad K., Raaschou–Nielsen O.: Genetic polymorphisms in CYP1B1, GSTA1, NQO1 andNAT2 and the risk of lung cancer. Cancer Lett., 2005; 221: 185-190
  Google Scholar
• 76. Stordal B., Davey M.: Understanding cisplatin resistance usingcellular models. IUBMB Life, 2007; 59: 696-699
  Google Scholar
• 77. Suk R., Gurubhagavatula S., Park S., Zhou W., Su L., Lynch T.J.,Wain J.C., Neuberg D., Liu G., Christiani D.C.: Polymorphisms inERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients.Clin. Cancer Res., 2005; 11: 1534-1538
  Google Scholar
• 78. Sun X., Li F., Sun N., Shukui Q., Baoan C., Jifeng F., Lu C., ZuhongL., Hongyan C., YuanDong C., Jiazhong J., Yingfeng Z.: Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapyin advanced non-small cell lung cancer patients. Lung Cancer,2009; 65: 230-236
  Google Scholar
• 79. Szczeklik A.: Choroby wewnętrzne. Tom I, Wydawnictwo MedycynaPraktyczna, Kraków 2005
  Google Scholar
• 80. Ushijima R., Takayama K., Izumi M., Harada T., Horiuchi Y., UchinoJ., Hara N., Nakanishi Y.: Immunohistochemical expression ofMRP2 and clinical resistance to platinum-based chemotherapy insmall cell lung cancer. Anticancer Res., 2007; 27: 4351-4358
  Google Scholar
• 81. Van Dyke A.L., Cote M.L., Wenzlaff A.S., Chen W., Abrams J., LandS., Giroux C.N., Schwartz A.G.: Cytokine and cytokine receptor single-nucleotidepolymorphisms predict risk for non-small cell lungcancer among women. Cancer Epidemiol. Biomarkers Prev., 2009;18: 1829-1840
  Google Scholar
• 82. Vogel U., Nexø B.A., Wallin H., Overvad K., Tjønneland A., Raaschou–Nielsen O.: No association between base excision repair gene polymorphismsand risk of lung cancer. Biochem. Genet., 2004; 42: 453-460
  Google Scholar
• 83. Wenzlaff A.S., Cote M.L., Bock C.H., Land S.J., Santer S.K.,Schwartz D.R., Schwartz A.G.: CYP1A1 and CYP1B1 polymorphismsand risk of lung cancer among never smokers: a population-basedstudy. Carcinogenesis, 2005; 26: 2207-2212
  Google Scholar
• 84. Wenzlaff A.S., Cote M.L., Bock C.H., Land S.J., Schwartz A.G.:GSTM1, GSTT1 and GSTP1 polymorphisms, environmental tobaccosmoke exposure and risk of lung cancer among never smokers: a population-basedstudy. Carcinogenesis, 2005; 26: 395-401
  Google Scholar
• 85. Wright C.M., Larsen J.E., Colosimo M.L., Barr J.J., Chen L., McLachlanR.E., Yang I.A., Bowman R.V., Fong K.M.: Genetic associationstudy of CYP1A1 polymorphisms identifies risk haplotypes in nonsmallcell lung cancer. Eur. Respir. J., 2010; 35: 152-159
  Google Scholar
• 86. Wu X., Lu C., Ye Y., Chang J., Yang H., Lin J., Gu J., Hong W.K.,Stewart D., Spitz M.R.: Germline genetic variations in drug actionpathways predict clinical outcomes in advanced lung cancer treatedwith platinum-based chemotherapy. Pharmacogenet. Genomics,2008; 18: 955-965
  Google Scholar
• 87. Wu X., Ye Y., Rosell R., Amos C.I., Stewart D.J., Hildebrandt M.A.,Roth J.A., Minna J.D., Gu J., Lin J., Buch S.C., Nukui T., Ramirez SerranoJ.L., Taron M., Cassidy A. i wsp.: Genome-wide association studyof survival in non-small cell lung cancer patients receiving platinum-basedchemotherapy. J. Natl. Cancer Inst., 2011; 103: 817-825
  Google Scholar
• 88. Yoh K., Ishii G., Yokose T., Minegishi Y., Tsuta K., Goto K., NishiwakiY., Kodama T., Suga M., Ochiai A.: Breast cancer resistanceprotein impacts clinical outcome in platinum-based chemotherapyfor advanced non-small cell lung cancer. Clin. Cancer Res., 2004;10: 1691-1697
  Google Scholar
• 89. Young L.C., Campling B.G., Cole S.P., Deeley R.G., Gerlach J.H.:Multidrug resistance proteins MRP3, MRP1, and MRP2 in lung cancer:correlation of protein levels with drug response and messengerRNA levels. Clin. Cancer Res., 2001; 7: 1798-1804
  Google Scholar
• 90. Zeng-Rong N., Paterson J., Alpert L., Tsao M.S., Viallet J., Alaoui-JamaliM.A.: Elevated DNA repair capacity is associated withintrinsic resistance of lung cancer to chemotherapy. Cancer Res.,1995; 55: 4760-4764
  Google Scholar
• 91. Zhou L.P., Luan H., Dong X.H., Jin G.J., Man D.L., Shang H.: Geneticvariants of CYP2D6 gene and cancer risk: a HuGE systematic reviewand meta-analysis. Asian Pac. J. Cancer Prev., 2012; 13: 3165-3172
  Google Scholar
• 92. Zienolddiny S., Campa D., Lind H., Ryberg D., Skaug V., StangelandL., Phillips D.H., Canzian F., Haugen A.: Polymorphisms of DNArepair genes and risk of non-small cell lung cancer. Carcinogenesis,2006; 27: 560-567
  Google Scholar

Full text